SMNR Semnur Pharmaceuticals, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1913577 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY87.9%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,344.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,757.8%
Debt / equity—
Current ratio0.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-580.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.44M | $1.25M | $1.27M | $714,000 | $1.14M | $502,000 | $187,000 | $235,000 |
| SG&A expense | $2.13M | $2.98M | $3.31M | $5.44M | $151.45M | $497,000 | $478,000 | $541,000 |
| Operating income | -$3.58M | -$4.22M | -$4.58M | -$6.16M | -$152.59M | -$999,000 | -$665,000 | -$776,000 |
| Interest expense | $56,000 | $123,000 | — | — | $0 | $0 | $26,974 | $26,692 |
| Net income | -$3.63M | -$4.35M | -$4.58M | -$6.16M | -$152.59M | -$999,000 | -$665,000 | -$167,306 |
| EBITDA | -$3.58M | -$4.22M | -$4.58M | -$6.16M | -$152.59M | -$999,000 | -$665,000 | -$776,000 |
| EPS (basic) | -0.02 | -0.02 | -0.02 | — | -0.76 | -0.01 | -0.01 | — |
| EPS (diluted) | -0.02 | -0.02 | -0.02 | — | -0.76 | -0.01 | -0.01 | — |
| Weighted avg. shares (diluted) | 224.23M | 230.21M | 230.21M | — | 201.69M | 200.00M | 200.00M | — |
| Banking | ||||||||
| Deposits | — | — | — | — | — | $123,107 | $120,482 | $75,292 |
| Balance sheet | ||||||||
| Cash & equivalents | $54,000 | $39,000 | $103,000 | $20,000 | $85,000 | $55,000 | $7,000 | $12,000 |
| Current assets | $1.26M | $1.19M | $1.22M | $596,000 | $85,000 | $14,144 | $2,736 | $6.00M |
| PP&E, net | $750,000 | $750,000 | $750,000 | $750,000 | $689,000 | — | — | $689,000 |
| Total assets | $2.01M | $1.94M | $1.97M | $1.35M | $774,000 | $562,462 | $9.15M | $6.68M |
| Current liabilities | $11.28M | $10.67M | $10.38M | $10.17M | $10.03M | $8.27M | $7.85M | $35,000 |
| Total liabilities | $35.31M | $31.62M | $27.30M | $22.10M | $15.37M | $11.16M | $10.74M | $49.47M |
| Shareholders' equity | -$33.31M | -$29.67M | -$25.33M | -$20.75M | -$14.59M | -$44.45M | -$43.45M | -$42.78M |
| Shares outstanding | 217.71M | 230.21M | 230.21M | 230.21M | 229.74M | — | — | 200.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.22M | -$2.14M | -$2.67M | -$3.60M | -$2.08M | $268,000 | -$399,000 | -$1.41M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $2.24M | $2.07M | $2.75M | $3.54M | $10.79M | -$220,000 | $394,000 | $1.41M |
| Depreciation & amortization | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-based compensation | $855,000 | $1.29M | $1.48M | $2.03M | $140.19M | $119,000 | $92,000 | $137,000 |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.